Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab Ravtansine in Advanced Pancreatic Cancer
NCT03023722Phase 2Completed
- Sponsor
- Yale University
- Start
- May 2017
- Primary completion
- Aug 2019
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of anetumab ravtansine in pancreatic cancer (PC), sponsored by Yale University. Started May 2017; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03023722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03023722.